Abstract Background Detection of HER2/neu receptor overexpression and/or amplification is a prerequisite for efficient anti-HER2 treatment of breast and gastric carcinomas. Immunohistochemistry (IHC) of the HER2 protein is the most common screening test, thus precise and reproducible IHC-scoring is of utmost importance. Interobserver variance still is a problem; in particular in gastric carcinomas the reliable differentiation of IHC scores 2+ and 1+ is challenging. Herein we describe the physical basis of what we called the ‘magnification rule’: Different microscope objectives are employed to reproducibly subdivide the continuous spectrum of IHC staining intensities into distinct categories (1+, 2+, 3+). Methods HER2-IHC was performed on 12...
This study investigated the degree of interlaboratory agreement when HER-2/neu was evaluated by immu...
Immunohistochemistry (IHC) plays an important role in evaluating the status of ER, PR, Ki-67 and hum...
In spite of the large number of studies on technical problems affecting the interlaboratory reproduc...
Abstract Background Detection of HER2/neu receptor ov...
Background: Detection of HER2/neu receptor overexpression and/or amplification is a prerequisite for...
The classification of human epidermal growth factor receptor 2 (HER2) expression is optimized to det...
AIMS: HER2 protein is over-expressed in 15-30% of breast carcinomas. Immunohistochemistry (IHC) is a...
Aims: Evaluating expression of the human epidermal growth factor receptor 2 (HER2) by visual examina...
HER2 is overexpressed in approximately 10%-20% of gastric and gastroesophageal junction carcinomas. ...
Background and Objective: Visual expression of invasive breast cancer with immunohistochemistry (IHC...
Figure S3. Scatter-plot of HER2 DAB-precipitates width and color intensity. For scoring intensities ...
Abstract—The HER2/neu protein is over-expressed in 20%-30 % of breast cancer cases, and is significa...
AIMS: Human epidermal growth factor receptor 2 (HER2) overexpression/amplification is implicated in ...
Abstract. The HER2 gene is amplified and overexpressed in 25–30 % of breast carcinomas. Assessment o...
Abstract Background Breast cancers that overexpress the human epidermal growth factor receptor 2 (HE...
This study investigated the degree of interlaboratory agreement when HER-2/neu was evaluated by immu...
Immunohistochemistry (IHC) plays an important role in evaluating the status of ER, PR, Ki-67 and hum...
In spite of the large number of studies on technical problems affecting the interlaboratory reproduc...
Abstract Background Detection of HER2/neu receptor ov...
Background: Detection of HER2/neu receptor overexpression and/or amplification is a prerequisite for...
The classification of human epidermal growth factor receptor 2 (HER2) expression is optimized to det...
AIMS: HER2 protein is over-expressed in 15-30% of breast carcinomas. Immunohistochemistry (IHC) is a...
Aims: Evaluating expression of the human epidermal growth factor receptor 2 (HER2) by visual examina...
HER2 is overexpressed in approximately 10%-20% of gastric and gastroesophageal junction carcinomas. ...
Background and Objective: Visual expression of invasive breast cancer with immunohistochemistry (IHC...
Figure S3. Scatter-plot of HER2 DAB-precipitates width and color intensity. For scoring intensities ...
Abstract—The HER2/neu protein is over-expressed in 20%-30 % of breast cancer cases, and is significa...
AIMS: Human epidermal growth factor receptor 2 (HER2) overexpression/amplification is implicated in ...
Abstract. The HER2 gene is amplified and overexpressed in 25–30 % of breast carcinomas. Assessment o...
Abstract Background Breast cancers that overexpress the human epidermal growth factor receptor 2 (HE...
This study investigated the degree of interlaboratory agreement when HER-2/neu was evaluated by immu...
Immunohistochemistry (IHC) plays an important role in evaluating the status of ER, PR, Ki-67 and hum...
In spite of the large number of studies on technical problems affecting the interlaboratory reproduc...